This proposal is based in part on recent studies showing that IDO expression can be blocked by inhibitors of c-KIT or mTOR (downstream of the c-KIT-PI3K-AKT pathway), with resultant potentiation of anti-tumor T cell responses (35). The gene discussed is IDO1; the disease is neoplasm.